N/A N=7 Continuous Glucose Monitoring to Measure Effect of Glycemic Index
Type 1 Diabetes Mellitus
Primary: Mean Area Under the Curve for Rise in Breakfast Post-prandial. — 61; 583 min x (mmol/l)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=7 Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
Postprandial Hypoglycemia
Primary: Mean Plasma Glucose Area Under the Curve (AUC 0-3h) — 22,192.5; 25,207.1; 21,715.9 mg*min/dl
N/A N=1,939 Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care
Type 2 Diabetes Mellitus · Prediabetic State
Primary: Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict…
Phase 3 N=60 Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment — -18.07; -103.56; -122.94 mg*h/dL…
Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
N/A N=200 Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy
Gestational Diabetes · Diagnoses Disease · Pregnancy in Diabetic
Primary: Number of Participants With a Positive Gestational Diabetes Mellitus (GDM) Screen (>= 140 mg/dL) on the 1 Hour 50-g Oral Glucose Tolerance Test (OGTT) — 31; 13…
N/A N=19 Post-Prandial Liver Glucose Metabolism in PCOS
Polycystic Ovarian Syndrome · Obesity · Hepatic Steatosis
Primary: Hepatic Fat Fraction — 8.35 Percent
Phase 4 N=72 A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Postprandial Pulse Wave Velocity (PWV) in Type 2 Diabetes Mellitus (T2DM) Participants at 30 Minutes (Mins) Pre-Breakfast — 10.99; 10.73; 11.56; 11.31 meters per second…
N/A N=26 Incretin Effect in People With Impaired Fasting Glucose
Obesity
Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min
N/A N=99 Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia
Type 1 Diabetes
Primary: The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch. — 146.69; 143.68; 149.02 mg/dl — p=.971
N/A N=40 Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients
Diabetes
Primary: Glycemic Index — 76.79; 86.92 percentage of AUC from GI100 — p=0.005
N/A N=34 Effects of an Apple Extract on Glycaemia: The GLU-Pomme Study
Prevention of Hyperglycaemia
Primary: Postprandial Glycaemia — 11.3; 15.2; 17.8; 27.1 mmol/L*min
Phase 4 N=20 Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
Prediabetes · Obesity
Primary: Monocyte NfkB Levels as Detected by Western Blotting — 62.79; 72.03; 67.68; 84.19 NfkB p65 arbitrary units
Phase 2 N=57 Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes
Diabetes, Gestational
Primary: Correlation Between Glucose AUC and Birth Weight. — 0.2902; 0.2935; 0.2915; 0.2859 correlation coefficient — p=0.035
N/A N=96 The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population
Impaired Fasting Glucose
Primary: Cmax for Glucose in IFG Status Participants — 42.76; 47.40 mg/dL — p=0.0487
N/A N=235 Point-of-Care Glucose Testing and Insulin Supplementation
Diabetes
Primary: Mean Fasting Blood Glucose — 162; 157 mg/dL
Phase 4 N=16 The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
Type 1 Diabetes Mellitus
Primary: Difference in the Two Hour and Four Hour Post Prandial Blood Glucose Levels Following Administration of Insulin Glulisine Versus Insulin Aspart at the End of the Twenty…
Phase 4 N=22 Incretins in Impaired Fasting Glucose
Pre-diabetes
Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05
Phase 4 N=14 Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001
Phase 2 N=16 Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia
Post-bariatric Hypoglycemia
Primary: Number of Participants With Meal-provoked Hypoglycemia, Defined as Sensor Glucose <65 mg/dL — 1; 5 participants — p=0.103
N/A N=50 Postpartum Continuous Glucose Monitoring (CGM) Study
Gestational Diabetes
Primary: Number of Participants With at Least 72 Hours of CGM Data Downloaded. — 43 Participants
N/A N=156 Glucose Control Using 1,5-AG Testing
Diabetes
Primary: Diagnosis-Treatment — 31.7; 35.0; 29.1; 31.9 CPV diagnosis-treatment percentage score
N/A N=39 Does the Use of Continuous Glucose Monitoring (CGM) in the Immediate Postpartum Period in Women With Pregestational Diabetes Admitted to the Hospital Decrease Hypoglycemic Episodes
Pregestational Diabetes
Primary: Number of Participants With Hypoglycemia During Postpartum Hospital Stay — 5; 2; 4; 5 participants
Phase 1 N=22 Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Insulin Resistance, Diabetes
Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146
Phase 4 N=5 Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients
Hepatitis B
Primary: Differences in Blood Glucose Levels as Measured by GNS-POC, GS-POC and Venous Blood Prior to and After HBIG Injection — -3.2; 6.0; 56.6; -2.6 mg/dL — p=0.59
N/A N=12 Glycemic Response Testing
Glycemic Index · Glycemic Response
Primary: Glycemic Response Measured as the Positive Incremental Area Under the Time-concentration Curve(iAUC) Calculated From Individual Glucose Measurements Upon Consumption of…
Phase 2 N=9 Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
Postbariatric Hypoglycemia
Primary: Glucose Nadir After Mizagliflozin Dosing — 6.2; 4.0; 17.5; 31.5 mg/dL
N/A N=15 The Acute Effects of Food Structure on Post Prandial Glucose and Subsequent Metabolic Responses
Obesity
Primary: Post-prandial Glucose Concentrations — 4.9; 4.8; 4.9; 5.01 mmol/l
N/A N=161 Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)
Type 1 Diabetes
Primary: Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports — 35; 29; 10 participants
N/A N=62 Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
Hypoglycemia · Obesity
Primary: Mean Serum Glucose Levels — 123.1; 157.5; 103.2; 138 mg/dl